Inavolisib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Inavolisib. Educational only — not medical advice.
Labeled uses
ITOVEBI, in combination with palbociclib and fulvestrant, is indicated for the treatment of adults with endocrine-resistant, PIK3CA -mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy [see Clinical Studies (14.1) ] .
Source: FDA labeling via NIH DailyMed (set 5de59f5b…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.